NOHO's CEO stated, "Tthe company has acquired the exclusive rights to an FDA registered medicine that will be manufactured as a new NOHO product for the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space as the product is backed by two published clinical studies."
The product's effectiveness is confirmed by two Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, NOHO has contracted the exclusive rights to the product in the Hangover market.
News 
Market Data 
Discover 
